Search

Key Clinical Message: This is the first case report of treatment with toceranib phosphate as postsurgical adjuvant chemotherapy for advanced FROMS. This reported case highlights the need for further studies on the efficacy of toceranib phosphate as adjuvant chemotherapy for FROMS. Feline restrictive orbital myofibroblastic sarcoma (FROMS) is a rare aggressive tumor in cats. We explored the effectiveness of using toceranib phosphate as postsurgical adjuvant chemotherapy for advanced FROMS in a 7‐year‐old cat. Despite treatment, the cat died 4 months after surgery. This report highlights the need for further studies on the efficacy of toceranib phosphate as adjuvant chemotherapy for FROMS. [ABSTRACT FROM AUTHOR]

Objective: To evaluate the postoperative visual outcome and complications of 25‐gauge pars plana vitrectomy (PPV) via a lateral approach without proptosis of the globe in dogs. Procedures: We reviewed the medical records of dogs diagnosed with giant rhegmatogenous retinal detachment (RRD) at Yokohama Animal Eye Clinic from 2016 to 2019 and treated by 25‐gauge PPV. Medical records included signalment, follow‐up time, etiology and duration of RRD, angle between the outermost trocar ports, immediate postoperative anatomic success rate, pre‐ and postoperative visual status, and postoperative complications. Results: Seventy‐two dogs (78 eyes, 13 breeds) were included. The most common breed was the Toy Poodle (48.6%), and the mean follow‐up time was 690.6 days. The most common etiology of RRD was cataract surgery (46.2%). The mean angle between the outermost trocar ports was 71.4º. Immediate postoperative anatomic success was noted in all eyes. Vision was regained or maintained in 87.2% of eyes, and the mean time to return of vision was 28.5 days. Maintenance of vision until the last known follow‐up was noted in 73.5% of eyes. The most common postoperative complication was glaucoma (40.3%), and glaucoma was the most common etiology of postoperative vision loss (88.9%). Conclusion: Twenty‐five gauge PPV via a lateral approach without proptosis of the globe is a successful method for treating canine giant RRD. [ABSTRACT FROM AUTHOR]

Objective: To describe the outcome of corneal collagen cross‐linking (CXL) combined with superficial keratectomy (SK) as treatment for corneal edema due to corneal endothelial dystrophy (CED) in dogs. Animals studied: Four eyes of four dogs (3 Shih Tzus and 1 English Cocker Spaniel) with corneal edema due to CED were treated with SK and CXL. Two were males, and two were females. Procedure: Depending on corneal thickness, 500‐700 μm of edematous cornea was removed by SK. Next, CXL was performed by irradiating the cornea with UVA (365 nm) at 3 mW/cm² irradiance for 30 min after soaking with 0.1% riboflavin in 20% dextran every three minutes for 30 minutes. One drop of riboflavin was instilled every three minutes during irradiation. Slit lamp biomicroscopy and optical coherence tomography were used to examine the cornea during the follow‐up period. Results: The corneas had focal to diffuse edema, and the average corneal thickness was 1553 (1282‐1900) μm. All corneas showed a significantly reduced corneal thickness and regained marked transparency immediately after treatment; however, the opacity increased as the corneal thickness increased during the follow‐up period. Corneal vascularization (n = 4) disappeared within a month. Corneal pigmentation (n = 1) and bullae (n = 1) were observed. All cases showed marked reduction in corneal thickness; however, transparency was improved in only one case. Conclusion: Collagen cross‐linking with SK has the potential to reduce the corneal thickness in CED cases; however, a lasting clinically significant improvement of corneal transparency seems unlikely. As the added benefit of CXL to the SK procedure is unclear based on the results of this study, combined treatment of CXL and SK for the treatment of corneal edema caused by CED is currently not recommended in dogs. [ABSTRACT FROM AUTHOR]